Introduction

Heart failure is the pathophysiological state characterized by ventricular dysfunction and associated clinical symptoms. It is a major cause of cardiovascular mortality and morbidity. Decreased systolic or diastolic cardiac function results in abnormal circulatory hemodynamics, activation of a variety of neurohormonal systems and retention of sodium and water. The integrity of the arterial circulation is determined by cardiac output and peripheral vascular resistance. Decrease in cardiac output or peripheral arterial vasodilatation causes arterial underfilling. That is an important signal which triggers multiple neurohormonal systems to maintain adequate arterial pressure and peripheral perfusion of the vital organs. The kidney is the principal organ affected when cardiac output declines. Alterations of hemodynamics and neurohormonal systems in heart failure result in renal sodium and water retention. Activation of sympathetic nervous system, renin-angiotensin-aldosterone system and non-osmotic vasopressin release stimulate the renal tubular reabsorption of sodium and water. Dysregulation of aquaporin-2 and sodium transporters also play an important role in the pathogenesis of renal sodium and water retention.

Key Words: heart failure; aquaporins, sodium-potassium-chloride symporters, sodium chloride symporters, epithelial sodium channel
brane of renal tubular epithelial cells were demonstrated. Low-frequency electrical stimulation of the renal nerves resulted in an antidiuretic and antinatriuretic response in the absence of changes in glomerular filtration rate (GFR) or renal plasma flow. Moreover, the protein expression of aquaporin (AQP) water channels was decreased in the denervated kidney. Renal denervation decreased sodium and water retention in experimental heart failure. In addition, the activation of renal nerves stimulates the renin-angiotensin-aldosterone system (RAAS) by stimulating renin release.

In heart failure, the RAAS is stimulated. Plasma renin activity, angiotensin II and aldosterone concentrations are increased. Angiotensin II is an important mediator of sodium and water retention in patients with heart failure. Angiotensin II directly enhances proximal tubular reabsorption of sodium and water. Angiotensin II receptor blocker treatment resulted in natriuresis in experimental heart failure. In addition, it was demonstrated that aldosterone antagonist spironolactone increased urinary sodium excretion in patients with heart failure.

In the kidney, natriuretic peptides (NPs) increase the GFR and urinary sodium excretion by afferent arteriolar vasodilation and efferent arteriolar constriction. Moreover, NPs inhibit sodium and water reabsorption induced by angiotensin II action in the proximal tubule and they directly inhibit sodium reabsorption in the collecting duct. NPs also inhibit renin release and aldosterone synthesis. The NPs are increased in heart failure. However, the renal responses of NPs were blunted in patients with heart failure. The resistance may be due to down-regulation of renal NP receptors, secretion of inactive immunoreactive NPs, increased degradation of NPs by neutral endopeptidase in the proximal tubule or decreased sodium delivery to the collecting duct as a result of increased sodium reabsorption in the proximal tubule.

Arginine vasopressin (AVP) is an antidiuretic hormone which is synthesized in the hypothalamus, stored in the posterior pituitary gland and released in response to increased osmolality or volume depletion. In the kidney, AVP causes antidiuresis by activating vasopressin V2 receptors on the basolateral membrane of the principal cells in the collecting duct. This process results in passive water reabsorption along the osmotic gradient. In heart failure, AVP secretion occurs despite a normal or even low plasma osmolality (non-osmotic AVP release). Arterial underfilling in heart failure contributes to the breakdown of baroreceptor-mediated suppression of AVP. In addition, angiotensin II stimulates the release of AVP by the stimulation of the thirst center of the brain. Thus, the dysregulation of AVP plays an important role in the development of hypoosmolar hyponatremia in patients with heart failure.

**Dysregulation of AQP and sodium transporters**

In the kidney, AQP water channels allow the movement of water across the tubular epithelium. AQP1 is abundant in the proximal tubule and descending thin limb and is essential for urinary concentration. AQP2 is exclusively expressed in the principal cells of the connecting tubule and collecting duct. It is regulated in the short-term and long-term by the AVP/Cyclic adenosine monophosphate (cAMP) pathway to increase osmotic water reabsorption. AQP3 is present in the basolateral membranes of collecting duct principal cells and represents exit pathways of water reabsorbed via AQP2 in the apical membranes.

In experimental heart failure, up-regulation of AQP2 has been documented. Nielsen et al. reported increased expression and targeting of AQP2 in association with hypo-natremia in experimental heart failure. Xu et al. also demonstrated up-regulation of AQP2 in chronic heart failure rats. In this study, the expression of AQP2 messenger RNA and protein was increased in association to increased plasma AVP levels in heart failure rats. V2 receptor antagonist treatment induced a significant diuresis, decrease in urinary osmolality and increase in plasma osmolality in heart failure rats. Up regulation of AQP2 in heart failure is inhibited by the treatment of V2 receptor antagonist. Moreover, it was demonstrated that V2 receptor antagonism decreases urinary AQP2 excretion in patients with chronic heart failure. These results suggest that upregulation of vasopressin and AQP2 plays an important role in
the development of water retention and hyponatremia in heart failure.

The renal sodium transporters play a critical role in the sodium reabsorption and regulation of extracellular fluid volume. The renal tubular sodium reabsorption is basically linked to the activity of \( \text{Na}^+\cdot\text{K}^+\)-ATPase that is heavily expressed in the basolateral membrane throughout the nephron segments\(^{33}\). The proximal tubule reabsorbs approximately two-thirds of the filtered sodium load. In this segment, type 3 \( \text{Na}^+/\text{H}^+ \) exchanger (NHE3) is mainly responsible for apical sodium reabsorption\(^{34}\). The bumetanide-sensitive \( \text{Na}^+/\text{K}^+\cdot2\text{Cl}^- \) cotransporter (NKCC2) is localized at the apical membrane of the thick ascending limb and mediates the apical \( \text{NaCl} \) transport in this water impermeable segment\(^{35}\). In the distal convoluted tubule, the thiazide-sensitive \( \text{Na}^+/\text{Cl}^- \) cotransporter (NCC) is involved in the apical movement of sodium\(^{36}\). On the other hand, epithelial sodium channel (ENaC) is expressed in the connecting tubule and collecting duct\(^{37}\).

Recently, altered regulations of renal sodium transporters in heart failure have been documented. Torp et al. demonstrated that the expression of NKCC2 was increased in heart failure rats. This change was decreased by losartan treatment. In addition, heart failure rats had increased basal and AVP stimulated cAMP accumulation in the thick ascending limb, which was abolished by losartan treatment\(^{38}\). These results may suggest that up-regulation of NKCC2 in heart failure rats plays a role in the increased sodium reabsorption in the thick ascending limb. The NKCC2 expression may be regulated by an interaction between V2 receptor and angiotensin II receptor. In addition, it was demonstrated that the expressions of AQP2, NHE3, NKCC2 and \( \alpha \)-ENaC were increased in heart failure rats, which were reversed or prevented by candesartan treatment\(^{39}\). These findings suggest that angiotensin II and the dysregulation of AQP2 and sodium transporters plays an important role in the pathogenesis of renal sodium and water retention in heart failure.

**Conclusions**

In heart failure, activation of SNS, RAAS, resistance to NPs and non-osmotic vasopressin release stimulate the renal tubular reabsorption of sodium and water. Dysregulation of AQP2 and sodium transporters also play an important role in the pathogenesis of renal sodium and water retention.

**References**

1) Ghali JK, Cooper R, Ford E: Trends in hospitalization rates for heart failure in the United States, 1973-1986. Evidence for increasing population prevalence. Arch Intern Med 150: 769-773, 1990
2) Rea ME, Dunlap ME: Renal hemodynamics in heart failure: implications for treatment. Curr Opin Nephrol Hypertens 17:87-92, 2008
3) Schrier RW, Abraham WT: Hormones and hemodynamics in heart failure. N Engl J Med 341:577-585, 1999
4) Schrier RW: Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy. N Engl J Med 319:1065-1072, 1988
5) Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN: Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 49:1659-1666, 1982
6) Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI: Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 73:615-621, 1986
7) Bell-Reuss E, Trevino DL, Gottschalk CW: Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption. J Clin Invest 57:1104-1107, 1976
8) DiBona GF: Neurogenic regulation of renal tubular sodium reabsorption. Am J Physiol 233:F73-81, 1977
9) Barajas L, Powers KV: Innervation of the thick ascending limb of Henle. Am J Physiol 255:F340-348, 1988
10) Lee J, Yoo K, Kim SW, et al.: Decreased expression of aquaporin water channels in denervated rat kidney. Nephron Physiol 103:p170-178, 2006
11) DiBona GF, Herman PJ, Sawin LL: Neural control of renal function in edema-forming states. Am J Physiol 254:R1017-1024, 1988
12) Sica DA: Sodium and water retention in heart failure and diuretic therapy: basic mechanisms. Cleve Clin J Med 73 (Suppl 2):S2-7, 2006
13) Watkins L, Jr., Burton JA, Haber E, Cant JR, Smith FW, Barger AC: The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. J Clin Invest 57:1606-1617, 1976
14) Liu FY, Cogan MG: Angiotensin II: a potent regulator of acidification in the rat early proximal convoluted tubule. J
15) Abassi ZA, Kelly G, Golomb E, Klein H, Keiser HR: Losartan improves the natriuretic response to ANF in rats with high-output heart failure. J Pharmacol Exp Ther 268: 224-230, 1994

16) Hensen J, Abraham WT, Durr JA, Schrier RW: Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am J Nephrol 11:441-446, 1991

17) Dunn BR, Ichikawa I, Pfeffer JM, Troy JL, Brenner BM: Renal and systemic hemodynamic effects of synthetic atrial natriuretic peptide in the anesthetized rat. Circ Res 59:237-246, 1986

18) Harris PJ, Thomas D, Morgan TO: Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature 326:697-698, 1987

19) Sonnenberg H, Honrath U, Chong CK, Wilson DR: Atrial natriuretic factor inhibits sodium transport in medullary collecting duct. Proc Natl Acad Sci U S A 250:F963-966, 1986

20) Cuneo RC, Espiner EA, Nicholls MG, Yandle TG, Brenner BM: Renal and systemic hemodynamic effects of synthetic atrial natriuretic peptide in the anesthetized rat. Circ Res 59:237-246, 1986

21) Burnett JC, Jr., Kao PC, Hu DC, et al.: Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 231:1145-1147, 1986

22) Wei CM, Heublein DM, Perrella MA, et al.: Natriuretic peptide system in human heart failure. Circulation 88:1004-1009, 1993

23) Cody RJ, Atlas SA, Laragh JH, et al.: Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 78:1362-1374, 1986

24) Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW: Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 305:263-266, 1981

25) Ma T, Yang B, Gillespie A, Carlson EJ, Epstein CJ, Verkman AS: Severely impaired urinary concentrating ability in transgenic mice lacking aquaporin-1 water channels. J Biol Chem 273:4296-4299, 1998

26) Nielsen S, DiGiovanni SR, Christensen EI, Knepper MA, Harris HW: Cellular and subcellular immunolocalization of vasopressin-regulated water channel in rat kidney. Proc Natl Acad Sci U S A 90:11663-11667, 1993

27) Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, Knepper MA: Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci U S A 92:1011-1017, 1995

28) Terris J, Ecelbarger CA, Nielsen S, Knepper MA: Long-term regulation of four renal aquaporins in rats. Am J Physiol 271:F414-422, 1996

29) Ecelbarger CA, Terris J, Frindt G, et al.: Aquaporin-3 water channel localization and regulation in rat kidney. Am J Physiol 269:F663-672, 1995

30) Nielsen S, Terris J, Andersen D, et al.: Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct. Proc Natl Acad Sci U S A 94:5450-5455, 1997

31) Xu DL, Martin PY, Ohara M, et al.: Uregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest 99:1500-1505, 1997

32) Martin PY, Abraham WT, Lieming X, et al.: Selective V2-receptor vasopressin antagonist decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 10:2165-2170, 1999

33) Kashgarian M, Biemesderfer D, Caplan M, Forbush B, 3rd: Monoclonal antibody to Na,K-ATPase: immunocytocchemical localization along nephron segments. Kidney Int 28:899-913, 1985

34) Amemiya M, Loffing J, Lotscher M, Kaisling B, Alpern RJ, Moe OW: Expression of NHE-3 in the apical membrane of rat renal proximal tubule and thick ascending limb. Kidney Int 48:1206-1215, 1995

35) Ecelbarger CA, Terris J, Hoyer JR, Nielsen S, Wade JB, Knepper MA: Localization and regulation of the renal Na(+)-K(+)-2Cl- cotransporter, BSC-1. Am J Physiol 271:F619-628, 1996

36) Plotkin MD, Kaplan MR, Verlander JW, et al.: Localization of the thiazide sensitive Na-Cl cotransporter, rTSC1 in the rat kidney. Kidney Int 48:170-183, 1996

37) Hager H, Kwon TH, Vinnikova AK, et al.: Immunocytochemical and immunoelectron microscopic localization of alpha-, beta-, and gamma-ENaC in rat kidney. Am J Physiol Renal Physiol 297:F1678-1688, 2001

38) Torp M, Brond L, Hadrup N, et al.: Losartan decreases vasoressin-mediated cAMP accumulation in the thick ascending limb of the loop of Henle in rats with congestive heart failure. Acta Physiol (Oxf) 190:339-350, 2007

39) Lutken SC, Kim SW, Jonassen T, et al.: Changes of renal AQP2, ENaC, and NHE3 in experimentally induced heart failure: response to angiotensin II AT1 receptor blockade. Am J Physiol Renal Physiol 297:F1678-1688, 2009